ADVANCED NON-SMALL CELL LUNG CANCER

This study is testing a new combination therapy called JSKN016 for people with advanced non-small cell lung cancer that has spread. The main goals are to see if the treatment is safe and if it helps shrink tumors. Researchers will enroll 288 adults in China who have not had certa…

This early-stage study is testing the safety and effects of an experimental cancer drug called PF-08046876 in adults with advanced solid tumors. The drug is an antibody drug conjugate designed to target and kill cancer cells. Researchers will give the drug through an IV to about …

This global Phase 3 trial is comparing a new drug called firmonertinib against two existing standard treatments for people with advanced non-small cell lung cancer that has specific, less common EGFR genetic mutations. The study aims to see if firmonertinib can better control the…

This early-phase study is testing whether adding two inhaled antibiotics to a standard immunotherapy drug (pembrolizumab) is safe and feasible for people with advanced non-small cell lung cancer. The idea is that bacteria in the lungs might help tumors grow, and treating these ba…

This study is testing a personalized cell therapy for adults with advanced non-small cell lung cancer that has stopped responding to standard treatments. Doctors remove a patient's tumor, grow special immune cells from it in a lab, and then infuse a large number of these 'tumor-f…

This program provides access to an investigational oral drug called sevabertinib for adults with advanced non-small cell lung cancer that has a specific genetic mutation (HER2). It's designed for people whose cancer has progressed after at least one prior treatment and who have n…

This study is testing whether a new drug called PF-08634404, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned…

This study is testing whether a new oral pill (BAY 2927088) works better and is safer than standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change called a HER2 mutation. About 278 adults who have not yet received t…

This study is testing whether the drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change called a MET exon 14 mutation. The trial is for patients whose cancer has worsened after at least one prio…

This study is testing whether a lower dose of chemotherapy, when combined with immunotherapy, is safer and easier to tolerate for older or frail adults with advanced lung cancer. The main goal is to see if this gentler approach causes fewer severe side effects that would force pa…

This study is testing whether a new drug called adagrasib works better alone or combined with an existing immunotherapy (pembrolizumab) for advanced lung cancer that has a specific genetic mutation called KRAS G12C. It will involve about 806 people who have not yet received treat…